scispace - formally typeset
Book ChapterDOI

56 – Autoantibodies in Rheumatoid Arthritis

Felipe Andrade, +2 more
- pp 804-817
About
The article was published on 2013-01-01. It has received 0 citations till now. The article focuses on the topics: Rheumatoid arthritis & Autoantibody.

read more

References
More filters
Journal ArticleDOI

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.

TL;DR: Relation entre risque de pemphigus et DW1eme et DRW6eme, et relation entre susceptibilite a la polyarthrite rhumatoide and un groupe d'epitopes trouves dans les sous-types non DW10 de DR4.
Journal ArticleDOI

Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

TL;DR: The onset and progression of autoantibody development before the clinical diagnosis of systemic lupus erythematosus is investigated, with a progressive accumulation of specificAutoantibodies before the onset of SLE, while patients are still asymptomatic.
Journal ArticleDOI

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

TL;DR: Anti-CCP antibody and RFs of all isotypes predated the onset of RA by several years, indicating that citrullination and the production of anti- CCP and RF autoantibodies are early processes in RA.
Journal ArticleDOI

Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors

TL;DR: In this article, the authors investigated the time course for the development of antibodies before onset of clinical RA and found that approximately half of patients with RA have specific serologic abnormalities several years before the onset of symptoms.
Journal ArticleDOI

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

TL;DR: The anti-CCP ELISA might be very useful for diagnostic and therapeutic strategies in RA of recent onset and appears to be highly specific for RA, using prevalent RA and non-RA sera.